Karpik Marta
Department of Clinical Orthopaedics and Traumatology, Medical University Hospital in Białystok.
Ortop Traumatol Rehabil. 2010 May-Jun;12(3):207-15.
The author presents the epidemiology, classification, clinical features and strategies of treatment of Giant Cell Tumor. Giant Cell Tumor of Bone accounts for 4-8% of primary bone tumors. It is most commonly seen in women aged 20 to 40 years. The most common sites are the distal femur and proximal tibia, distal radius, and proximal humerus. Increasing pain at the tumor site is the most common presenting symptom. Three types of GCT can be distinguished radiographically according to the Cappanacci or Enneking classification. The mainstay of treatment is total mechanical removal with curettage. The recurrence rate is high (12-50%) during the first 2-3 years after surgery, regardless of pre-operative tumor stage. 5-7% cases of giant cell tumor produce malignant recurrences, usually after five to more than 10 years after surgery.
作者介绍了骨巨细胞瘤的流行病学、分类、临床特征及治疗策略。骨巨细胞瘤占原发性骨肿瘤的4% - 8%。最常见于20至40岁的女性。最常见的部位是股骨远端和胫骨近端、桡骨远端和肱骨近端。肿瘤部位疼痛加剧是最常见的首发症状。根据卡帕纳奇（Cappanacci）或恩neking分类，在X线片上可区分出三种类型的骨巨细胞瘤。治疗的主要方法是刮除术加彻底的机械性切除。无论术前肿瘤分期如何，术后头2至3年的复发率都很高（12% - 50%）。5% - 7%的骨巨细胞瘤病例会发生恶性复发，通常在术后5至10多年后。
